Inhibition of tumor angiogenesis and melanoma growth by targeting vascular E-selectin

Ann Surg. 2011 Sep;254(3):450-6; discussion 456-7. doi: 10.1097/SLA.0b013e31822a72dc.

Abstract

Objectives: Aggressive human melanomas express, C-X-C chemokine receptor 4 (CXCR4), the receptor for the chemokine, stromal cell-derived factor-1alpha (SDF-1α). The CXCR4-SDF-1α axis has been postulated to increase melanoma invasiveness. We discovered that SDF-1α specifically upregulates E-selectin on endothelial cells, thus tethering circulating endothelial progenitor cells (EPC) and facilitating homing. We investigated the hypothesis that small interfering ribonucleic acid (siRNA)-mediated E-selectin blockade inhibits melanoma angiogenesis and tumor growth.

Methods: Human melanoma cells overexpressing SDF-1α were xenografted on severe combined immunodeficiency (SCID) mice. SDF-1α expression in cells was measured by enzyme-linked immunosorbent assay (ELISA). In vitro melanoma cell growth was examined by cell proliferation assay. In vivo vascular E-selectin knockdown was achieved by administration of high-volume E-selectin siRNA (100 pmol/180 μL/week × 3 times) and inhibition was validated by immunostaining (N = 6/group, E-Selectin siRNA vs control siRNA). Tumor angiogenesis was quantified (DiI-perfusion and LASER confocal microscopy). EPC homing to tumor vasculature was detected by immunostaining. Explanted in vivo tumor size and weight were measured.

Results: Three melanoma cells tested expressed undetectable levels of SDF-1α. Additional enforced overexpression of SDF-1α (by Lenti-SDF-1α) increased melanoma cell growth both in vitro and in vivo, enhanced EPC homing to tumor tissue, and increased tumor angiogenesis. Knocking-down vascular E-selectin significantly inhibited SDF-1α-induced EPC homing, tumor angiogenesis, and decreased melanoma growth in vivo.

Conclusions: Downregulation of vascular E-selectin profoundly inhibits EPC homing, tumor angiogenesis, and tumor growth in human melanoma xenograft murine model, potentially by suppression of E-selectin-mediated EPC-endothelial cells interactions/homing. These findings identify E-selectin as a novel target for inhibition of melanoma angiogenesis and tumor growth.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Chemokine CXCL12 / drug effects*
  • Chemokine CXCL12 / metabolism
  • Down-Regulation
  • E-Selectin / drug effects*
  • E-Selectin / genetics*
  • E-Selectin / metabolism
  • Enzyme-Linked Immunosorbent Assay
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Melanoma, Experimental / drug therapy*
  • Melanoma, Experimental / genetics*
  • Melanoma, Experimental / metabolism
  • Mice
  • Mice, SCID
  • Neovascularization, Pathologic / drug therapy*
  • Neovascularization, Pathologic / metabolism
  • RNA, Small Interfering / therapeutic use*
  • Transplantation, Heterologous
  • Treatment Outcome
  • Up-Regulation

Substances

  • Chemokine CXCL12
  • E-Selectin
  • RNA, Small Interfering